Annexon adds Month 24 dual primary endpoint to Phase 3 ARCHER II trial of vonaprument in geographic atrophy

• Annexon expanded its Phase 3 ARCHER II trial of vonaprument in geographic atrophy by adding a Month 24 dual primary endpoint.
• Results have not been presented; a Data Monitoring Committee assessment of the Month 15 primary endpoint is expected in Q4 2026.
• The change broadens the trial’s path to success by allowing efficacy at either Month 15 or Month 24.
• An open-label extension study will start, offering monthly vonaprument to patients completing Month 24 to assess longer-term safety and benefit.
• Month 24 analyses are expected to complete in Q3 2027, setting up a later readout beyond the initial milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120600PRIMZONEFULLFEED9808414) on August 12, 2026, and is solely responsible for the information contained therein.